Lawmakers to address 2012 NCPA Legislative Conference attendees
ALEXANDRIA, Va. — In anticipation of its 2012 Legislative Conference next month, the National Community Pharmacists Association unveiled its lineup of congressional speakers who will discuss pressing healthcare and pharmacy issues with pharmacists.
The current program for NCPA’s 2012 Legislative Conference, which will be held May 7 to 9 in Washington, D.C., includes Sens. Jerry Moran, R-Kan., and Sherrod Brown, D-Ohio, as well as Reps. Dave Camp, R-Mich.-4th; Frank Pallone, D-N.J.; Aaron Schock, R-Ill.; and Mike Ross, D-Ark.
"We commend these members of Congress for supporting patients’ access to independent community pharmacies and for their plans to speak during our Legislative Conference," NCPA CEO Douglas Hoey said. "Our members look forward to visiting them and talking face-to-face about how Medicaid cuts, MAC pricing, abusive audits, mandatory mail order, and other issues are hurting small business pharmacies and pharmacists’ ability to serve their patients."
Valeant buys product lines from Atlantis Pharma for $71 million
MONTREAL — Valeant Pharmaceuticals International is acquiring "certain assets" of a drug maker based in Mexico.
Valeant said Wednesday that it would buy gastric, analgesic and anti-inflammatory drugs from branded generics manufacturer Atlantis Pharma for $71 million. The products had sales of $26 million last year.
"Atlantis Pharma’s well-known brands in Mexico, and the potential to expand our export business to Central America and the Andean region, make this a strong addition to our current operations in Mexico," Valeant chairman and CEO J. Michael Pearson said. "The ability to combine these assets with our existing operations in Mexico should provide distinct commercial synergies for our overall business."
Roche ends bid to buy diagnostics firm
BASEL, Switzerland — Roche has decided not to buy diagnostics firm Illumina, the drug maker said Wednesday.
Roche said it had decided not to extend its $51-per-share offer for Illumina following the reelection of Illumina’s incumbent directors. Roche offered to buy Illumina for $44.50 per share in January, increasing the offer to $51 on March 29. The company took the offer directly to shareholders earlier this month after Illumina’s board rejected it.
"We continue to hold Illumina and its management in very high regard, but, with access only to public information about Illumina’s business and prospects, we do not believe that a price above Roche’s offer for Illumina of $51 per share would be in the interest of Roche’s shareholders," Roche CEO Severin Schwan said. "We have throughout this process desired to engage in a constructive dialogue with Illumina’s management, listen to its views of value and prospects and offer a fair and adequate price for Illumina’s shareholders. But in the absence of such discussions, our duty to be disciplined with the assets of Roche’s shareholders has led to this decision."